Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Bosentan (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases; Pulmonary arterial hypertension
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Oct 2015 New source identified and integrated (NCT00637065); ClinicalTrials.gov.
- 01 Oct 2015 New trial record